Cubist Buys Trius, Optimer for New Hospital Antibiotics
This article is for subscribers only.
Cubist Pharmaceuticals Inc. agreed to buy Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc. for as much as $1.62 billion, gaining approved and experimental antibiotics for its roster of medicines.
Cubist will acquire San Diego-based Trius for $13.50 a share or about $707 million in cash, a premium of 15 percent over yesterday’s closing price. Trius shareholders also will get a contingent value right of as much as $2 for each share they own for sales milestones, bringing the value of the deal to as much as $818 million, the companies said in a statement.